Company news

Elixiron Immunotherapeutics (Cayman) Limited news

Latest news releases, newest first.

View company

Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease

June 10, 2026

Decks